Portal de Periódicos da CAPES

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2

2013; Oxford University Press; Volume: 15; Issue: 8 Linguagem: Inglês

10.1093/neuonc/not088

1523-5866

Brian M. Alexander, Patrick Y. Wen, Lorenzo Trippa, David A. Reardon, W.K. Alfred Yung, Giovanni Parmigiani, D. A. Berry,

Cancer Genomics and Diagnostics

The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.